Counterfeit Drug Task Force Report: June 2006

Department of Health and Human Services logo   Department of Health and Human Services

Public Health Service
Food and Drug Administration
Rockville MD 20857
DATE:June 8,2006

Randall Lutter, Ph.D.
Associate Commissioner for Policy and Planning

Margaret Glavin
Associate Commissioner for Regulatory Affairs

FROM:Andrew vonEschenbach, MD
Acting Commissioner of Food and Drugs


Thank you for submitting to me the Counterfeit Drug Task Force Report - 2006 Update. I strongly concur that increasing the safety and security of the nation's drug supply and protecting it from the increasing sophisticated threat of counterfeit drugs is critically important. I commend you and the rest of the Counterfeit Drug Task Force on your efforts in developing this report and its recommendations to further this goal. I appreciate the fact-finding efforts that the Task Force undertook, such as holding the February 2006 public workshop and soliciting public comment, to understand the issues and provide me with informed recommendations. 

I endorse the report and its recommendations. This includes the recommendation not to further extend the stay and to issue a compliance policy guide (CPG) that discusses FDA's enforcement focus regarding pedigree requirements. Please move forward with these recommendations, pursuant to FDA's good guidance practice (GGP) process (21 CFR § 10.1 15), as appropriate.


Dr. von Eschenbach's signature

Page Last Updated: 04/18/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English